Clinical application of poly(ADP-ribose) polymerase inhibitors in high-grade serous ovarian cancer

Oncologist

Volumn 21, Issue 5, 2016, Pages 586-593

  Parkes, Eileen E ^a   Kennedy, Richard D ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Almac Sciences   (United Kingdom)

Author keywords

Biomarkers, cancer; DNA damage; Genes, BRCA1; Genes, BRCA2; Ovarian cancer; Poly(ADP ribose)polymerase inhibitors

Indexed keywords

ATR PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CEDIRANIB; CEP 9722; DOXORUBICIN; GEMCITABINE; INIPARIB; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PACLITAXEL; RUCAPARIB; TALAZOPARIB; TEMOZOLOMIDE; VELIPARIB; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; EUROPEAN MEDICINES AGENCY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICITY; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; FEMALE; GENETICS; MUTATION; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR GENE;

BIOMARKERS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MUTATION; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 84966447555     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0438     Document Type: Article

References (84)

1. Ferlay Y, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer, 2013. [Internet], Available at http://globocan.iarc.fr. Accessed October 30, 2015.
2. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609–615.
3. Turner N, Tutt A, Ashworth A. Hallmarks of “BRCAness” in sporadic cancers. Nat Rev Cancer 2004;4:814–819.
4. Vencken PM, Kriege M, Hoogwerf D et al. Chemosensitivity and outcome of BRCA1- and BRCA2- associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011;22:1346–1352.
5. Tan DS, Rothermundt C, Thomas K et al. “BRCAness” syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2mutations. J ClinOncol 2008; 26:5530–5536.
6. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009;361:1475–1485.
7. The Nobel Prize in Chemistry. 2015. [Internet]; 2015. Available at http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2015/. Accessed October 19, 2015.
8. Kennedy RD, D’Andrea AD. DNA repair pathways in clinical practice: Lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006; 24:3799–3808.
9. Shen Y, Lee YH, Panneerselvam J et al. Mutated Fanconi anemia pathway in non-Fanconi anemia cancers. Oncotarget 2015;6:20396–20403.
10. Kennedy RD, D’Andrea AD. The Fanconi anemia/ BRCA pathway: New faces in the crowd. Genes Dev 2005;19:2925–2940.
11. Niedzwiedz W, Mosedale G, Johnson M et al. The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell 2004;15:607–620.
12. Khanna KK, Jackson SP. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 2001;27:247–254.
13. Taniguchi T, Garcia-Higuera I, Andreassen PR et al. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD 51. Blood 2002;100:2414–2420.
14. Shigechi T, Tomida J, Sato K et al. ATR-ATRIP kinase complex triggers activation of the Fanconi anemia DNA repair pathway. Cancer Res 2012;72: 1149–1156.
15. Tomida J, Itaya A, Shigechi T et al. A novel interplay between the Fanconi anemia core complex and ATR-ATRIP kinase during DNA cross-link repair. Nucleic Acids Res 2013;41:6930–6941.
16. Willis NA, Chandramouly G, Huang B et al. BRCA1 controls homologous recombination at Tus/ Ter-stalled mammalian replication forks. Nature 2014;510:556–559.
17. Chandramouly G, Willis NA, Scully R. A protective role for BRCA2 at stalled replication forks. Breast Cancer Res 2011;13:314.
18. Vyas S, Chesarone-Cataldo M, Todorova T et al. A systematic analysis of the PARP protein family identifies new functions critical for cell physiology. Nat Commun 2013;4:2240.
19. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Mol Oncol 2011;5:387–393.
20. Ström CE, Johansson F, Uhlèn M et al. Poly (ADPribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res 2011;39:3166–3175.
21. Bryant HE, Petermann E, Schultz N et al. PARPis activated at stalled forks to mediate Mre11- dependent replication restart and recombination. EMBO J 2009;28:2601–2615.
22. Gottipati P, Vischioni B, Schultz N et al. Poly(ADPribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010;70: 5389–5398.
23. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917–921.
24. Bryant HE, Schultz N, Thomas HD et al. Specific killingofBRCA2-deficienttumourswith inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913–917.
25. Hartwell LH, Szankasi P, Roberts CJ et al. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997;278:1064–1068.
26. O’Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple negative breast cancer. N Engl JMed 2011;364:205–214.
27. O’Shaughnessy J, Schwartzberg L, Danso MA et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014;32:3840–3847.
28. Liu X, Shi Y, Maag DX et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012;18:510–523.
29. Patel AG, DeLorenzo SB, Flatten K S et al. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res 2012;18:1655–1662.
30. Novello S, Besse B, Felip E et al. A phase II randomized study evaluating the additionof iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. Ann Oncol 2014;25:2156–2162.
31. Penson RT, Whalen C, Lasonde B et al. Aphase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2011;29(suppl):5004.
32. Mateo J, Ong M, Tan DS et al. Appraising iniparib, the PARP inhibitor that never was—What must we learn? Nat Rev Clin Oncol 2013;10:688–696.
33. Fong PC, Boss DS, Yap TA et al. Inhibitionof poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl JMed 2009;361:123–134.
34. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRC Acarrier ovarian cancer correlating with platinum free interval. J Clin Oncol 2010;28:2512–2519.
35. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002;45:73–85.
36. Tentori L, Leonetti C, Scarsella M et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003;9:5370–5379.
37. Muñoz-Gàmez JA, Martìn-Oliva D, Aguilar- Quesada R et al. PARP inhibition sensitizes p53- deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 2005;386:119–125.
38. Donawho CK, Luo Y, Luo Y et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13: 2728–2737.
39. van der Noll R, Ang JE, Jager A et al. Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors. J Clin Oncol 2013;31(suppl):2579.
40. Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADPribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30:372–379.
41. Safra T, Borgato L, Nicoletto M et al. Pegylated liposomal doxorubicin (PLD) treatmentfor recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations. J Clin Oncol 2010;28(suppl):5043.
42. Oza AM, Cibula D, Benzaquen AO et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial. Lancet Oncol 2015;16:87–97.
43. Liu JF, Barry WT, Birrer M et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study. Lancet Oncol 2014;15:1207–1214.
44. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl JMed 2012;366:1382–1392.
45. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinumsensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852–861.
46. Frampton JE. Olaparib: A review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs 2015;29:143–150.
47. Praga C, Bergh J, Bliss J et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005;23:4179–4191.
48. Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 2007;7:152.
49. NDA206162, Olaparib (Lynparza), AstraZeneca, June 25, 2014. [Internet]. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM402207.pdf. Accessed October 23, 2015.
50. Kaufman B, Shapira-Frommer R, Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244–250.
51. Shapira-Frommer R, Oza AM, Domchek SM et al. A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation. J Clin Oncol 2015;33:5513.
52. McNeish IA, Oza AM, Coleman RL et al. Results of ARIEL2: A phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J Clin Oncol 2015;33: 5508.
53. Moore KN, DiSilvestro P, Lowe ES et al. SOLO1 andSOLO2: R and omizedphase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). J Clin Oncol 2014;32(suppl): TPS5616.
54. Molife LR, Mateo J, McGoldrick T et al. Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor olaparib, in ovarianandbreastcancer patients with BRCA1/2mutations. J Clin Oncol 2012; 30:3048.
55. Mateo J, Friedlander M, Sessa C et al. Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation. Eur J Cancer 2013;49 (suppl):801.
56. Hennessy BT, Timms KM, Carey MS et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010;28:3570–3576.
57. Baldwin RL, Nemeth E, Tran H et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res2000; 60:5329–5333.
58. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564–569.
59. Geisler JP, Hatterman-Zogg MA, Rathe JA et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002;94:61–67.
60. D’Andrea AD. The Fanconi Anemia/BRCA signaling pathway: Disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2003;2:290–292.
61. Taniguchi T, Tischkowitz M, Ameziane N et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9: 568–574.
62. Hughes-Davies L, Huntsman D, Ruas M et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115:523–535.
63. Zhang S, Yuan Y, Hao D. A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy. PLoS One 2014;9:e113169.
64. Sun J, McNeish I, Coleman RL et al. A novel companion diagnostic predicts response to the PARP inhibitor rucaparib in ovarian cancer. [Abstract] In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; Apr 18-22, 015; Philadelphia, PA. Cancer Res 2015; 75(suppl):4670.
65. Sun JX, Frampton G, Wang K et al. A computational method for somatic versus germline variant status determination from targeted next-generation sequencing of clinical cancer speciments without a matched normal control. [Abstract] In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; April 5-9, 2014; San Diego, CA: AACR. Cancer Res 2014;74:1893.
66. Abkevich V, Timms KM, Hennessy BT et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012;107:1776–1782.
67. Birkbak NJ, Wang ZC, Kim JY et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012;2:366–375.
68. Popova T, Maniè E, Rieunier G et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012;72:5454–5462.
69. Timms KM, Abkevich V, Hughes E et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 2014;16:475.
70. Norquist B, Wurz KA, Pennil CC et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008–3015.
71. Mulligan JM, Hill LA, Deharo S et al. Identification and validation of an anthracycline/cyclophosphamide based chemotherapy response assay in breast cancer. J Natl Cancer Inst 2014;106: djt335.
72. Hill LA, Mulligan JM, Deharo S et al. DNA damage response deficiency signature predicts response to platinum-based therapy in ovarian cancer. Eur J Cancer 2013;49(suppl):956.
73. Turkington RC, Hill LA, McManus D et al. Association of a DNA damage response deficiency (DDRD) assay and prognosis in early-stage esophageal adenocarcinoma. J Clin Oncol 2014;32(suppl):4015.
74. Mukhopadhyay A, Elattar A, Cerbinskaite A et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010;16:2344–2351.
75. Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in BRCA 2. Nature 2008;451:1111–1115.
76. Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008;105:17079–17084.
77. Rottenberg S, Nygren AO, Pajic M et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007;104:12117–12122.
78. Amiri-Kordestani L, Basseville A, Kurdziel K et al. Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 2012;15:50–61.
79. Jaspers JE, Kersbergen A, Boon U et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1- mutated mouse mammary tumors. Cancer Discov 2013;3:68–81.
80. Xu G, Chapman JR, Brandsma I et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 2015;521:541–544.
81. Boersma V, Moatti N, Segura-Bayona S et al. MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 59 end resection. Nature 2015; 521:537–540.
82. Johnson N, Johnson SF, Yao W et al. Stabilization ofmutantBRCA1protein confers PAR Pinhibitor and platinum resistance. Proc Natl Acad Sci USA 2013;110:17041–17046.
83. Shen Y, Rehman FL, Feng Y et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 2013;19:5003–5015.
84. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer 2012;12:68–78.